<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01252797</url>
  </required_header>
  <id_info>
    <org_study_id>F100528006</org_study_id>
    <nct_id>NCT01252797</nct_id>
  </id_info>
  <brief_title>Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)</brief_title>
  <acronym>RAD 1002</acronym>
  <official_title>RAD 1002: Phase I Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, and effectiveness of changing the
      order of receiving radiation therapy for treating brain cancer.  The investigators hope that
      changing the sequence of radiation therapy will lower the risk of cancer spreading
      throughout your spinal fluid, which covers your brain and spinal cord.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>to investigate the maximum tolerated dose (MTD) of preoperative stereotactic radiosurgery (SRS) for brain metastasis</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate acute toxicity, late toxicity, technical feasibility, and to estimate rates of local control and leptomeningeal dissemination with preoperative stereotactic radiosurgery (SRS).</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Group A will start at dose level II: 15 Gy
Group B will start at dose level I: 12 Gy</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who have brain metastases and will undergo both surgery and radiation therapy for
        treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must have history of histologically confirmed malignancy.  Brain biopsy
             is not required unless diagnosis is judged to be in doubt by the treating physician.

          -  Newly diagnosed brain metastases (four or fewer by post-contrast MRI obtained within
             six weeks of study entry)

          -  At least one brain metastasis (index tumor) must be within 2-6 cm in maximum diameter
             and deemed appropriate for surgical resection by the treating neurosurgeon.

          -  Karnofsky performance status (KPS) of greater than or equal to 60 (Appendix B)

          -  Age greater than 19

          -  Life expectancy greater than 12 weeks

          -  Subjects given written informed consent

        Exclusion Criteria:

          -  Patients with small cell lung cancer and lymphoma are ineligible.

          -  More than four metastases by baseline post-contrast MRI

          -  Prior whole brain radiation therapy

          -  Insufficient recovery from all active toxicities of prior therapies

          -  Subjects who are deemed to be poor surgical risks by the treating neurosurgeon
             because of medical comorbidities

          -  Pregnant or nursing women

          -  Women of childbearing potential who are not using an effective method of
             contraception are excluded.  Women of childbearing potential must have a negative
             urine or serum pregnancy test within 24 hours prior to administration of SRS.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John B. Fiveash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hazelrig-Salter Radiation Oncology Center (HSROC)/ University of Alabama at Birmingham (UAB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Messer, RN, OCN</last_name>
    <phone>205-975-2880</phone>
    <email>amesser@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hazelrig-Salter Radiation Oncology Center/University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Messer, RN, OCN</last_name>
      <phone>205-975-2880</phone>
      <email>amesser@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>John B Fiveash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Stewart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Spencer, MD, MSHA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruby F. Meredith, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rojymon Jacob, MD, FCRP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Popple, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael C. Dobelbower, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Markert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barton Guthrie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Riley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Winfield Fisher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Cantor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grant Clark, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>John Fiveash, MD</investigator_full_name>
    <investigator_title>Professor and Vice Chair, University of Alabama at Birmingham Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>brain metastases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
